Carlo Gambacorti-Passerini | Academic Influence

Carlo Gambacorti-Passerini's AcademicInfluence.com Rankings

Carlo Gambacorti-Passerini

Medical

#896

World Rank

#1157

Historical Rank

Hematology

#22

World Rank

#25

Historical Rank

Oncology

#135

World Rank

#139

Historical Rank

medical Degrees

Carlo Gambacorti-Passerini

Philosophy

#9254

World Rank

#12788

Historical Rank

Logic

#6242

World Rank

#7743

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Carlo Gambacorti-Passerini's Degrees

Doctorate Medicine University of Milan
PhD Hematology University of Milan

Why Is Carlo Gambacorti-Passerini Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Carlo Gambacorti-Passerini is an Italian oncologist and hematologist known for his contributions to cancer research. He is Professor of Internal Medicine and Hematology at the University of Milan Bicocca in Italy and Director of the Hematology Department at S. Gerardo Hospital, Monza, Italy. He was Senior Investigator and Head of the Oncogenic Fusion Proteins Unit at the National Cancer Institute, Milan Italy from 1990 to 2003, and Professor of Oncology and Hematology at McGill University, Montreal, Quebec, Canada, from 2004 to 2007.

(See a Problem?)

Carlo Gambacorti-Passerini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) (2065)
Clinical and biological implications of driver mutations in myelodysplastic syndromes. (2013) (1493)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. (2011) (1090)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. (2013) (878)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. (2000) (536)
Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. (2002) (483)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. (2011) (418)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. (2012) (417)
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. (2009) (412)
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. (1999) (394)
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. (2011) (388)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. (1998) (373)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. (2003) (369)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. (2006) (356)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. (2007) (349)
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. (2000) (347)
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia (2012) (343)
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. (1997) (336)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. (2018) (309)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. (2012) (301)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017) (300)
BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 (2002) (288)
Crizotinib in anaplastic large-cell lymphoma. (2011) (250)
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. (1998) (230)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. (2008) (223)
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (2020) (220)
Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation (2007) (218)
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. (1998) (201)
α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients (2003) (201)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase (2008) (194)
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. (2002) (188)
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells (2008) (181)
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. (2009) (170)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial (2014) (164)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study (2015) (161)
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations (2013) (157)
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. (1993) (134)
hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis (2002) (128)
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. (2006) (127)
Cancer procoagulant in human tumor cells: evidence from melanoma patients. (1986) (124)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells (2007) (124)
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. (2011) (120)
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. (2003) (119)
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. (2010) (114)
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. (2015) (113)
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. (1993) (110)
Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. (1996) (102)
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. (2008) (99)
Integrative pathway enrichment analysis of multivariate omics data (2018) (96)
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia (2014) (95)
ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. (2002) (94)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up (2014) (94)
Gynaecomastia in men with chronic myeloid leukaemia after imatinib (2003) (94)
Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting* (2007) (91)
Chronic myeloid leukemia: reminiscences and dreams (2016) (87)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors (2012) (85)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia (2019) (84)
Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors (2012) (82)
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis (2020) (80)
Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib (2016) (76)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase (2013) (75)
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. (2017) (75)
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK (2015) (72)
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase* (2008) (70)
Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib (2016) (69)
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes (2018) (67)
Part I: Milestones in personalised medicine--imatinib. (2008) (67)
Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. (2003) (67)
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. (2006) (66)
Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors (2015) (66)
Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. (2002) (66)
Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. (1999) (66)
In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid. (1996) (62)
Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. (2005) (61)
Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation (2011) (60)
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. (2016) (59)
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. (2010) (59)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial (2012) (58)
Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. (2010) (58)
Inhibition of RET tyrosine kinase by SU5416. (2006) (58)
Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study (2018) (58)
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. (2006) (58)
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. (2008) (56)
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase–Activated Leukemias (2015) (55)
Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism* (2011) (54)
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. (2018) (53)
Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial (2014) (53)
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. (1990) (52)
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice (2019) (51)
Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene. (1998) (51)
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma (2014) (50)
FTY 720 , a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome – positive acute lymphocytic leukemia (2007) (49)
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. (2015) (49)
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction (2020) (48)
Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. (2010) (48)
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma (2018) (48)
Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib. (2008) (47)
Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells (2012) (46)
In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. (1999) (46)
Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. (1988) (46)
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. (2010) (44)
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub (2018) (44)
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV (2010) (43)
In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. (2006) (43)
Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. (2004) (43)
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. (2010) (42)
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients (2009) (42)
Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL. (2007) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Cells and cytokines in immunotherapy and gene therapy of cancer. (1999) (40)
Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid. (2001) (39)
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (2010) (39)
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 (1988) (39)
Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib (2015) (38)
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review (2018) (37)
Imatinib concentrations in human milk. (2007) (37)
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery (2012) (37)
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study (2018) (37)
Constitutive degradation of PML/RARα through the proteasome pathway mediates retinoic acid resistance (1999) (36)
Binding of imatinib by alpha(1)-acid glycoprotein. (2002) (36)
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome‐Positive Leukemias (2017) (36)
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. (2015) (36)
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. (2007) (36)
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies (2005) (36)
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. (2011) (36)
Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. (2010) (35)
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency (2016) (35)
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype (2005) (35)
Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. (2002) (35)
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene (2015) (34)
Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. (2010) (34)
ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells (2011) (34)
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. (2006) (34)
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib (2008) (34)
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. (1996) (33)
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 (2015) (33)
Expression, purification, and inhibition of human RET tyrosine kinase. (2005) (32)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (2020) (32)
Combined burden and functional impact tests for cancer driver discovery using DriverPower (2020) (31)
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells (2009) (31)
Chronic myeloid leukemia: Second‐line drugs of choice (2016) (30)
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. (2013) (30)
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. (2007) (30)
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY (2017) (29)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up (2011) (28)
ALK a Novel Lymphoma-associated Tumor Antigen for Vaccination Strategies (2003) (27)
Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study (2012) (26)
Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib (2007) (26)
VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples (2020) (25)
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study (2012) (25)
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease (2001) (25)
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study (2021) (25)
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data (2013) (25)
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. (1986) (24)
Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. (2000) (24)
Morgana acts as an oncosuppressor in chronic myeloid leukemia. (2015) (24)
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target (2020) (24)
A Phase I Study of Recombinant Interleukin 2 in Melanoma Patients. Toxicity and Clinical Effects (1987) (23)
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. (2003) (23)
Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells (1991) (23)
Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy (2005) (23)
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. (1987) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML). (2007) (22)
An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. (2005) (22)
ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis (2007) (22)
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation (2013) (21)
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung (2004) (21)
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. (2020) (21)
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY (2018) (21)
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial (2020) (21)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma (2015) (21)
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia (2018) (21)
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (2019) (20)
Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors (2011) (20)
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance (1989) (19)
Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up. (2011) (19)
Effects of 1,25-dihydroxy vitamin D3 on all-trans retinoic acid sensitive and resistant acute promyelocytic leukemia cells. (1996) (19)
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. (1997) (19)
Molecular cytogenetics of the acute promyelocytic leukemia‐derived cell line NB4 and of four all‐trans retinoic acid–resistant subclones (2002) (19)
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib (2015) (19)
The role of bosutinib in the treatment of chronic myeloid leukemia. (2019) (19)
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. (2019) (19)
Immune response to autologous human melanoma: implication of class I and II MHC products. (1986) (19)
RET kinase inhibitors: a review of recent patents (2012–2015) (2017) (18)
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib (2010) (18)
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma (2020) (18)
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib (2005) (18)
Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib. (2013) (18)
Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia (2014) (17)
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy. (2022) (17)
Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line. (2011) (17)
Acute promyelocytic leukaemia cells resistant to retinoic acid show further perturbation of the RAR alpha signal transduction system. (1995) (17)
Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). (2010) (17)
Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy (2017) (17)
Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib (2020) (17)
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2 (1993) (16)
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy (2020) (16)
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. (2014) (16)
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (2012) (16)
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. (2003) (16)
A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target. (2008) (16)
High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients (2013) (16)
Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL (2008) (16)
A Phase II Study of the Administration of Recombinant Interleukin 2 (rIL-2) Plus Lymphokine Activated Killer (LAK) Cells in Stage IV Melanoma Patients (1989) (16)
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients (2005) (15)
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib. (2014) (15)
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. (2021) (15)
OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes (2016) (15)
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine (2020) (15)
How I treat newly diagnosed chronic myeloid leukemia in 2015 (2015) (15)
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases (2013) (15)
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. (2015) (15)
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. (2010) (15)
The ALK gene, an attractive target for inhibitor development. (2011) (14)
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate (2005) (14)
Pregnancy outcomes in patients treated with bosutinib (2018) (14)
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia (2019) (14)
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial (2022) (14)
High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. (2011) (14)
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial (2012) (14)
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia (2019) (13)
IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. (2020) (13)
Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial (2013) (13)
Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY). (2014) (12)
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. (2018) (12)
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients (2017) (12)
Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. (2017) (12)
Differential lysis of melanoma clones by autologous recombinant interleukin 2‐activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx) (1988) (12)
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial (2015) (11)
The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition (2017) (11)
Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial (2013) (11)
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML) (2019) (11)
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells1 (2018) (11)
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations (2020) (11)
Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies (2013) (11)
Effect of imatinib on haematopoietic recovery following idarubicin exposure (2003) (11)
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop (2013) (10)
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation. (1989) (10)
Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors (2011) (10)
Giardia and giardiasis. (1994) (10)
Reply to P. Laneuville et al (2010) (10)
Deferasirox in the management of iron‐overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON‐M study) (2019) (9)
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules. (1992) (9)
Corrigendum: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' (2007) (9)
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (2020) (9)
Acute myeloid leukaemia niche regulates response to L‐asparaginase (2019) (9)
BCR‐ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation (1998) (9)
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. (1993) (9)
PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (2012) (9)
Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial (2012) (9)
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes (2017) (9)
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. (2020) (9)
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells (2004) (8)
Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). (2011) (8)
Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy (2019) (8)
Choosing the right TKI for chronic myeloid leukemia: When the truth lies in “long‐term” safety and efficacy (2011) (8)
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. (2006) (8)
Binding of imatinib by α1-acid glycoprotein. Authors' reply (2002) (8)
Acid Glycoprotein Binds to Imatinib ( STI 571 ) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients 1 (2003) (8)
Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months (2018) (8)
Characterization of compound 584, an Abl kinase inhibitor with lasting effects (2008) (8)
Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation. (2020) (8)
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis (2016) (7)
Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (2012) (7)
Problems, controversies, and perspectives on the clinical use of interleukin-2. (1990) (7)
BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. (2012) (7)
Human CD 4 Lymphocytes Specifically Recognize a Peptide Representing the Fusion Region of the Hybrid Protein pml / RARa Present in Acute Promyelocytic Leukemia Cells (2003) (7)
Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes (2018) (7)
Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells (2004) (7)
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia (2020) (7)
Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection (2021) (6)
O-001 Clinical and biological implications of gene mutations in MDS (2013) (6)
In Vivo Effects of Multiple Cycles of Recombinant Interleukin-2 (IL2) on Peripheral Granulocyte-macrophage Hematopoietic Progenitors Circulating in the Blood of Cancer Patients (1991) (6)
Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies (1986) (6)
Long ‐ term effects of crizotinib in ALK ‐ positive tumors ( excluding NSCLC ) : A phase 1 b open ‐ label study (2019) (6)
Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial (2018) (6)
How “precise” is precision medicine in hematology? (2017) (6)
Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study (2014) (6)
Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up (2017) (6)
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts). (2012) (6)
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma (2021) (6)
Can Similarities between the Pathogenesis of Preeclampsia and COVID-19 Increase the Understanding of COVID-19? (2022) (6)
Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study (2019) (5)
Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY) (2013) (5)
Observational Study of CML Italian Patients Who Discontinued TKIs (2017) (5)
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population (2019) (5)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update (2012) (5)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update (2012) (5)
HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins (1997) (5)
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) (2013) (5)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial (2017) (5)
Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia (2016) (5)
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. (2014) (5)
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia (2012) (5)
Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (5)
Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial (2018) (5)
Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months (2015) (5)
Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment. (2004) (5)
Imbalanced Angiogenesis in Pregnancies Complicated by SARS-CoV-2 Infection (2022) (4)
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. (2022) (4)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib (2012) (4)
Predictors of performing response monitoring in patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY). (2014) (4)
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias. (2021) (4)
Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) (2014) (4)
Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop (2011) (4)
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy (2021) (4)
Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib. (2012) (4)
Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial (2012) (4)
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data (2020) (4)
A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer (1988) (4)
Free needles for drug addicts: don't forget the syringe. (1988) (4)
Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2019) (4)
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation (2019) (4)
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update. (2018) (4)
Decrease of resistance to imatinib in leukaemia (2002) (4)
Of nicks and time. (2001) (4)
The Role of the Immune System in Anti-Tumour Responses (1995) (4)
Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias. (2010) (4)
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea (2018) (3)
Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. (2008) (3)
Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study (2017) (3)
High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic (2012) (3)
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase (2014) (3)
Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients (2010) (3)
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis (2014) (3)
Immunogenicity of fusion proteins (1993) (3)
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer. (2006) (3)
Oncogenic protein tyrosine kinases (2004) (3)
Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (2017) (3)
The role of the immune system in anti-tumour responses. Potential for drug therapy. (1995) (3)
Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients (2020) (3)
Quantification of Intra-Host Genomic Diversity of SARS-CoV-2 Allows a High-Resolution Characterization of Viral Evolution and Reveals Functionally Convergent Variants (2020) (3)
Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers (2019) (3)
Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. (2019) (3)
ALK inhibitors for clinical use in cancer therapy. (2016) (3)
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases (2014) (3)
Binding of imatinib by α1-acid glycoprotein [5] (multiple letters) (2002) (3)
CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma (2021) (3)
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies (2021) (3)
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success (2022) (3)
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase (2022) (3)
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML). (2019) (3)
The privacy of medical records. (2001) (3)
Using the Second-Generation ALK Inhibitor AP 26113 in Human NPM-ALK – Positive Anaplastic Large Cell Lymphoma (2015) (3)
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling (2018) (3)
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study (2022) (3)
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial (2020) (2)
Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study (2014) (2)
Federal Privacy of Medical Information Act. (1979) (2)
Oncogenic tyrosine kinases. (2004) (2)
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study. (2021) (2)
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia (2022) (2)
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV (2022) (2)
Prostatectomy or watchful waiting in prostate cancer. (2003) (2)
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK) (1988) (2)
Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results (2015) (2)
Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy. (2013) (2)
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study (2020) (2)
Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure. (2015) (2)
Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party (2019) (2)
Decrease of resistance to imatinib in leukaemia [3] (multiple letters) (2002) (2)
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study. (2020) (2)
Role of the drug transporters in the multidrug resistance affecting bosutinib treatment (2011) (2)
Management and outcome of 11 pregnancies in women with polycythemia vera. (2019) (2)
RNA‐seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients (2015) (2)
Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients (2013) (2)
Highly Sensitive Mutations Detection in BCR-ABL Positive Leukemia Prior and during Imatinib Treatment. (2004) (2)
Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML (2015) (2)
Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study (2015) (2)
Long term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas: a monocentric analysis. (2022) (2)
SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia (2013) (2)
PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL (2019) (2)
Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update (2017) (2)
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. (2009) (2)
Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study (2018) (2)
Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience (2019) (2)
AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial. (2022) (2)
Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (2011) (2)
Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib (2010) (2)
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase. (2022) (2)
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia (2014) (2)
Deregulated Activity and Localization of Glycogen Synthase Kinase 3β In Chronic Myeloid Leukemia Progenitors: Role In Leukemia Maintenance and Targeted Therapy. (2010) (1)
Alpha 1 acid glycoprotein (AGP) binds to STIS71 and alters its tissue distribution and intracellul4r concentrations (2000) (1)
Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. (2006) (1)
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis (2011) (1)
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage (2021) (1)
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia (2021) (1)
An example of tumor-specific/transformation-related antigens (1993) (1)
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 (2021) (1)
Author Correction: Integrative pathway enrichment analysis of multivariate omics data (2020) (1)
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) (2019) (1)
Australian College of Paediatrics. Policy statement. Soy protein formula. (1987) (1)
Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results (2021) (1)
Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (2020) (1)
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial (2021) (1)
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia. (2021) (1)
Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients. (2009) (1)
P-027 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia (2013) (1)
An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization (2019) (1)
nucleic acid leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide In vitro transcription and translation inhibition by anti-promyelocytic (2011) (1)
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. (2019) (1)
Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera (2018) (1)
IMPAIRED GENERATION OF PROCOAGULANT ACTIVITY IN LEUKAEMIC MONOBLASTS (1986) (1)
Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial (2017) (1)
Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (2020) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
PNAs as novel cancer therapeutics (2003) (1)
Infusion of Autologous Alloactivated Lymphocytes in Melanoma Patients: Toxicity and Immunologic Monitoring (1986) (1)
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma (2013) (1)
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition (2009) (1)
Simultaneous development of Philadelphia chromosome‐positive and ‐negative leukemias in the same patient (2006) (1)
Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update (2013) (1)
PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (2019) (1)
Inhibitors of the RET Tyrosine Kinase Based on a 2‐(Alkylsulfanyl)‐4‐(3‐thienyl) Nicotinonitrile Scaffold. (2010) (1)
New developments in the treatment of ALK-driven malignancies (2012) (1)
Generation and Verification of a Three-Dimensional Model of the ALK Kinase Domain: ALK - a “Supermutant” of Abl. (2004) (1)
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors (2015) (1)
Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib. (2009) (1)
Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy (2022) (1)
Treatment Ef fi cacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP 26113 in Human NPM-ALK – Positive Anaplastic Large Cell Lymphoma (2015) (1)
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study (2021) (1)
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea (2018) (1)
Beyond Desegregation -- What Ought to Be Done (1973) (1)
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 (2010) (1)
TYROSINE KINASE INHIBITOR (TKI) SWITCHING : EXPERIENCE FROM SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS IN CLINICAL PRACTICE (2014) (1)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
ALK-positive lymphomas to ALK inhibition (2011) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO) (2020) (0)
Federal Privacy of Medical Information Act. (1980) (0)
Leukemia Cells by Anti-PML Peptide Nucleic Acid and PML Expression in Acute Promyelocytic α Receptor-Inhibition of Promyelocytic Leukemia ( PML ) / Retinoic Acid Updated (2001) (0)
Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY) (2022) (0)
BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL (2017) (0)
a abl, PDGF-receptor and / or kit receptor-tyrosine kinase inhibitor with an organic substance which binds combination of alpha1-acidic glycoprotein (2000) (0)
Immunomodulation in Cancer Patients Treated with Interleukin-2. Induction of Non-Specific and Specific Immune Responses (1993) (0)
inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with (2014) (0)
P717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL (2022) (0)
Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy (2017) (0)
Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients (2020) (0)
Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial. (2018) (0)
The immune response to oncogenic fusion proteins (2001) (0)
present in acute promyelocytic leukemia cells representing the fusion region of the hybrid protein pml/RAR alpha Human CD4 lymphocytes specifically recognize a peptide (2011) (0)
Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia (2019) (0)
H.R.5862 - A bill to repeal the Federal requirement of incremental pricing under the Natural Gas Policy Act of 1978. (1979) (0)
Abstract 4715: Characterization of potential co-drivers of pathogenesis in ALK positive ALCL (2020) (0)
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study. (2020) (0)
Tyrosin-Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis (2015) (0)
The 14q32.31 DLK1-DIO3 MIR300 tumor suppressor promotes leukemogenesis by inducing cancer stem cell quiescence and inhibiting NK cell anti-cancer immunity (2019) (0)
CLINICAL TRIALS AND OBSERVATIONS Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and / or nilotinib therapy failure Running head : Bosutinib in CP CML after second-generation TKIs (2005) (0)
Federal Privacy of Medical Information Act. [(Title provided[ (1979) (0)
Original Article Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line (2011) (0)
Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2019) (0)
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients (2019) (0)
Whole-Exome Sequencing Data – Identifying Somatic Mutations (2014) (0)
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort (2022) (0)
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706) (2022) (0)
Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia (2022) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al (2005) (0)
Abstract 3719: Mechanisms of resistance to the second-generation alk inhibitor ap26113 in human npm-alk-positive anaplastic large cell lymphoma cells (2014) (0)
ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia (2015) (0)
Abstract 951: Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-β-catenin-modulator miR-300 in leukemic stem/progenitor proliferation and survival in CML (2016) (0)
Peptides ALK (anaplastic lymphoma kinase) immunogenic. (2002) (0)
Identification of Novel Point Mutations in Splicing Sites by the Integration of Exome and RNA Sequencing Data in Myeloproliferative Diseases (2011) (0)
Transfusion of autologous, alloactivated helper-enriched lymphocytes obtained by cytapheresis to patients with melanoma (1986) (0)
Caution in using second generation TKI, especially for first line therapy of CML. (2022) (0)
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene (2015) (0)
Failure of polymyxin B to restore sensitivity to quinolones for Pseudomonas aeruginosa. (1989) (0)
Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma (2022) (0)
Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1 (2006) (0)
Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. (2007) (0)
Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY) (2014) (0)
Correction to “Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase” (2022) (0)
Response to Chand et al (2004) (0)
PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL (2019) (0)
[Travel diarrhea. Causes, diagnosis, therapy]. (1978) (0)
Free needles for drug addicts: dont forget the syringe [letter] (1988) (0)
Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial : 18-Month Follow-up (2018) (0)
PS1181 DOSING PATTERNS OF DASATINIB AND NILOTINIB USE IN SIMPLICITY, AN OBSERVATIONAL STUDY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE (2019) (0)
The functional role of activation loop tyrosines residues in the autoregulation of ALK catalytic activity (2006) (0)
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years, (2011) (0)
Cost for intravenous immunoglobulin in children can vary 25% by packaging alone. (1987) (0)
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients (2023) (0)
leukemogenesis oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL Identification of novel post-transcriptional targets of the BCR/ABL (2013) (0)
Abstract #4418: Dissection of the RET/beta-catenin interaction in the thyroid cancer line TPC1 (2009) (0)
An Observational Study of Survival in Patients with Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY): CML‐264 (2018) (0)
Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. (2005) (0)
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib (2015) (0)
Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial (2019) (0)
ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine (2020) (0)
The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience (2018) (0)
Managing Information Technology Change in the Decade of the SO ' s Proceedings of : DoD Long Range ADP Planning Conference (2015) (0)
P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL (2022) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
Privacy of Medical Records Act. (1979) (0)
Cells to Lysis by Interleukin 2-activated Lymphocytes Susceptibility of Chemoresistant Murine and Human Tumor (2006) (0)
Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma (2019) (0)
Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial (2017) (0)
The human molecular genetics network. (1995) (0)
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub (2018) (0)
Cancer esearch apeutics , Targets , and Chemical Biology orectal Tumors Are Effectively Eradicated by Combined bition of β-Catenin , KRAS , and the Oncogenic R nscription Factor ITF 2 (2010) (0)
CHAPTER 11 PNAs as Novel Cancer Therapeutics (0)
Retaining Parental Role Despite the Presence of Hematological Neoplastic Diseases: The Emanuela Project and the Role of the Hematologist (2018) (0)
Interleukin-2 biology and immunology (1993) (0)
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter (2014) (0)
Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study (2022) (0)
Author response for "Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL)" (2019) (0)
Abstract 3385: ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity (2018) (0)
Hypofractionated Whole Breast Radiotherapy Adapting to the Evidence (2016) (0)
Long-term efficacy and cardiac, vascular and hypertension safety of Bosutinib in previously treated patients with Philadelphia chromosome-positive leukemia (2018) (0)
inhibition acute lymphoblastic leukemia, and its reversal by histone deacetylase in glucocorticoid poor-responsive pediatric BIM Epigenetic silencing of (2012) (0)
Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial. (2022) (0)
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE trial) : 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels (2018) (0)
Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice (2018) (0)
Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure. (2015) (0)
Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study (2022) (0)
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia (2015) (0)
1030P Poor outcome of double-protein expressor diffuse large B-cell lymphoma (2018) (0)
CML-277: Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study (2020) (0)
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates (2017) (0)
H.R.10014 - A bill to amend the Federal Trade Commission Act (15 U.S.C. 44, 45) to provide that under certain circumstances exclusive territorial arrangements shall not be deemed unlawful. (1973) (0)
Records' confidentiality at risk without new legislation. (1980) (0)
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma (2018) (0)
Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK (2011) (0)
Whole-Exome Sequencing of 8 Atypical Chronic Myeloid Leukaemia Patients, (2011) (0)
MYC-ID3 Pathway in a Cohort of Diffuse Large B Cell Lymphomas: Immunoistochemical Analysis and Prognostic Implications (2016) (0)
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION (2018) (0)
Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study (2017) (0)
Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization. (2023) (0)
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience. (2022) (0)
Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis Is a Predictor of Venous Thrombosis and Poor Outcome in Patients with Prefibrotic Primary Myelofibrosis (2022) (0)
Privacy: the public's view. (1979) (0)
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia (2014) (0)
Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6 th Post-ASH International CML and Myeloproliferative Neoplasms Workshop (2013) (0)
Privacy of medical records. (1978) (0)
Too many agencies spoil Euro research (1999) (0)
First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). (2023) (0)
Abl inhibitor BMS354825 binding mode in Ableson kinase revealed by molecular docking studies (2005) (0)
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS (2022) (0)
Oncoproteins as Tumor-Specific Antigens (2000) (0)
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi (2023) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract 902: In vitro and in vivo characterization of resistance to lorlatinib treatment in ALK mutated cancers (2018) (0)
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins (2005) (0)
-morgana haploinsufficiency causes in mice a lethal and transplantable CML like myeloid neoplasm -morgana is underexpressed in aCML and in a subgroup of CMLs where predicts a worse response (0)
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas (2022) (0)
Identification of SETBP1 As an Epigenetic Hub Protein That Induces the Transcription of a Network of Development-Related Genes (2017) (0)
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes. (1988) (0)

This paper list is powered by the following services:

Other Resources About Carlo Gambacorti-Passerini

en.wikipedia.org

What Schools Are Affiliated With Carlo Gambacorti-Passerini?

Carlo Gambacorti-Passerini is affiliated with the following schools:

Image Attributions

Image Source for Carlo Gambacorti-Passerini